title: [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
abstract: OBJECTIVE
  The aim of this study was to determine whether the expressions of excision repair cross-complementing-1 (ERCC1) and thymidylate synthase (TS) predict the clinical outcome of patients with esophageal squamous cell carcinoma treated with CDDP/5-FU chemoradiotherapy.
  
  
  METHODS
  Fifteen patients with esophageal squamous cell carcinoma underwent CDDP/5-FU chemoradiotherapy. Immunohistochemical staining for ERCC1 and TS was performed using endoscopic biopsy specimens obtained prior to chemoradiotherapy. We then evaluated the response to treatment. The MIB-1 index, and the expressions of p53, p21, bax and bcl-2 were also investigated.
  
  
  RESULTS
  ERCC1 expression was strongly detected in all of the cases. No significant relationship was observed between the response to treatment and the intensity of staining, or the percentage of cells stained. The MIB-1 index and the expressions of p53, p21, bax and bcl-2 were not associated with the response to chemoradiotherapy.
  
  
  CONCLUSIONS
  In the present study, we found that the expressions of ERCC1 and TS were not suitable as predictors of the response to chemoradiotherapy.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000032:analysis; D004268:DNA-Binding Proteins / Q000032:analysis*; D004720:Endonucleases / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000737:chemistry* / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D013940:Thymidylate Synthase / Q000032:analysis*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D051028:bcl-2-Associated X Protein / Q000032:analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004268:DNA-Binding Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin; D005472:Fluorouracil